Trial Profile

An Open-label Multicenter Rollover Study to Provide Continued Treatment to Participants Previously Enrolled in a RVU120 Clinical Study

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RVU 120 (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours
Focus Adverse reactions
Acronyms ROVER-01
Sponsors Ryvu Therapeutics

Most Recent Events

24 Sep 2025 Planned initiation date changed from 7 Aug 2025 to 15 Dec 2025.
18 Sep 2025 According to Ryvu Therapeutics media release, data from the trial anticipated in Q4 2025.
23 May 2025 Status changed from planning to not yet recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com